Neuroprotective effect of combining tanshinone IIA with low‑dose methylprednisolone following acute spinal cord injury in rats

Yao,Nian‑Wei; Lu,Yuan; Shi,Li‑Qi; Xu,Feng; Cai,Xian‑Hua

doi:10.3892/etm.2017.4271

Neuroprotective effect of combining tanshinone IIA with low‑dose methylprednisolone following acute spinal cord injury in rats

Authors:
- Nian‑Wei Yao
- Yuan Lu
- Li‑Qi Shi
- Feng Xu
- Xian‑Hua Cai
View Affiliations

Affiliations: Department of Orthopedics, The Third Affiliated Hospital of Nanjing University of Traditional Chinese Medicine, Nanjing Hospital of Traditional Chinese Medicine, Nanjing, Jiangsu 210000, P.R. China, Department of Neurology, Nantong First People's Hospital, Nantong, Jiangsu 226000, P.R. China, Department of Orthopedics, Yuyao Hospital of Traditional Chinese Medicine, Ningbo, Zhejiang 315000, P.R. China, Department of Orthopedics, Wuhan General Hospital of Guangzhou Military Command, Wuhan, Hubei 430070, P.R. China
Published online on: March 28, 2017 https://doi.org/10.3892/etm.2017.4271
Pages: 2193-2202
Copyright: © Yao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study compared the potential neuroprotective effect of tanshinone IIA (TIIA) monotherapy, methylprednisolone (MP) monotherapy and combined treatment in an adult acute spinal cord injury (ASCI) rat model. The current study used the weight‑drop method (Allen's Impactor) in the rat model and the mechanical scratch method in primary spinal cord neuron culture to determine whether the combined treatment was able to reduce the required dosage of MP in the treatment of ASCI to produce a similar or improved therapeutic effect. In vivo male Sprague Dawley rats (n=60) were randomly divided into 5 groups, of which 12 rats were selected for the sham group and T9‑T11 laminectomies, leading to ASCI, were performed on 48 of the 60 rats using a 10 g x25 mm weight‑drop at the level of T10 spinal cord. Therefore, the ASCI group (n=12) included the ‘laminectomy and weight‑drop’. The remaining 36 ASCI model animals were subdivided into 3 groups (n=12 each group): TIIA group (30 mg/kg/day), MP group (30 mg/kg) and combined treatment group (TIIA 30 mg/kg/day + MP 20 mg/kg). Neuronal function following ASCI was evaluated using the Basso Beattie Bresnahan (BBB) locomotor rating scale. Levels of the anti‑apoptotic factor B‑cell lymphoma‑2 (Bcl‑2), the pro‑apoptotic factors Bcl‑2 associated protein X (Bax) and caspase‑3, and the inflammatory associated factor nuclear factor‑κB, were analyzed by western blot analysis. Immunohistochemistry was used to detect caspase‑3. To investigate the underlying mechanism, the anti‑oxidative effect of combination TIIA and MP treatment was assessed by measuring the activity of malondialdehyde (MDA) and superoxide dismutase (SOD) in ASCI. In agreement with the experiment in vivo, primary neurons were prepared from the spinal cord of one‑day‑old Sprague‑Dawley rats' and co‑cultured with astrocytes from the brain cortex. The injury of neurons was induced by mechanical scratch and levels of apoptosis factors were analyzed by western blot analysis. The results of the current study indicated that injured animals in the combined treatment group exhibited a significant increase in BBB scores (P<0.05). TIIA + MP combined treatment and MP treatment was observed to reduce the expression of pro‑apoptotic factors and promote neuron survival in vivo and in vitro. Combined treatment may promote neuroprotection through reduced apoptosis and inflammation caused by ASCI, similar to MP alone. Combined treatment reversed the decrease of SOD and the increase of MDA level caused by ASCI. In addition, combined treatment decreased the expression of caspase‑3 in the neurons following ASCI in rats, as indicated by immunofluorescence double labeling. Overall, the present study indicates that the combined treatment of TIIA and MP may protect the neurons by stimulating the rapid initiation of neuroprotection following ASCI and reduce the dosage of MP in the treatment of ASCI required to produce the same or improved neuroprotective effects in vivo and in vitro.

View Figures

View References

1	Singh A, Tetreault L, Kalsi-Ryan S, Nouri A and Fehlings MG: Global prevalence and incidence of traumatic spinal cord injury. Clin Epidemiol. 6:309–331. 2014.PubMed/NCBI
2	Evaniew N, Belley-Côté EP, Fallah N, Noonan VK, Rivers CS and Dvorak MF: Methylprednisolone for the treatment of patients with acute spinal cord injuries: A systematic review and meta-analysis. J Neurotrauma. 33:468–481. 2016. View Article : Google Scholar : PubMed/NCBI
3	Choi DW and Rothman SM: The role of glutamate neurotoxicity in hypoxic-ischemic neuronal death. J Neurotrauma. 13:171–182. 1990.
4	Emery E, Aldana P, Bunge MB, Puckett W, Srinivasan A, Keane RW, Bethea J and Levi AD: Apoptosis after traumatic human spinal cord injury. J Neurosurg. 89:911–920. 1998. View Article : Google Scholar : PubMed/NCBI
5	Hall ED and Braughler JM: Free radicals in CNS injury. Res Publ Assoc Res Nerv Ment Dis. 71:81–105. 1993.PubMed/NCBI
6	Blight AR: Macrophages and inflammatory damage in spinal cord injury. J Neurotrauma. 9:(Suppl 1). S83–S91. 1992.PubMed/NCBI
7	Lou J, Lenke LG, Ludwig FJ and O'Brien MF: Apoptosis as a mechanism of neuronal cell death following acute experimental spinal cord injury. Spinal Cord. 36:683–690. 1998. View Article : Google Scholar : PubMed/NCBI
8	Yin X, Yin Y, Cao FL, Chen YF, Peng Y, Hou WG, Sun SK and Luo ZJ: Tanshinone IIA attenuates the inflammatory response and apoptosis after traumatic injury of the spinal cord in adult rats. PLoS One. 7:e383812012. View Article : Google Scholar : PubMed/NCBI
9	Silva NA, Sousa N, Reis RL and Salgado AJ: From basics to clinical: A comprehensive review on spinal cord injury. Prog Neurobiol. 114:25–57. 2014. View Article : Google Scholar : PubMed/NCBI
10	Kwon BK, Tetzlaff W, Grauer JN, Beiner J and Vaccaro AR: Pathophysiology and pharmacologic treatment of acute spinal cord injury. Spine J. 4:451–464. 2004. View Article : Google Scholar : PubMed/NCBI
11	Oh SK and Jeon SR: Current concept of stem cell therapy for spinal cord injury: A review. Korean J Neurotrauma. 12:40–46. 2016. View Article : Google Scholar : PubMed/NCBI
12	Bracken MB, Shepard MJ, Collins WF Jr, Holford TR, Baskin DS, Eisenberg HM, Flamm E, Leo-Summers L, Maroon JC, Marshall LF, et al: Methylprednisolone or naloxone treatment after acute spinal cord injury: 1-year follow-up data. Results of the second national acute spinal cord injury study. J Neurosurg. 76:23–31. 1992. View Article : Google Scholar : PubMed/NCBI
13	Bracken MB, Shepard MJ, Collins WF, Holford TR, Young W, Baskin DS, Eisenberg HM, Flamm E, Leo-Summers L, Maroon J, et al: A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the second national acute spinal cord injury study. N Engl J Med. 322:1405–1411. 1990. View Article : Google Scholar : PubMed/NCBI
14	Bracken MB, Collins WF, Freeman DF, Shepard MJ, Wagner FW, Silten RM, Hellenbrand KG, Ransohoff J, Hunt WE, Perot PL Jr, et al: Efficacy of methylprednisolone in acute spinal cord injury. JAMA. 251:45–52. 1984. View Article : Google Scholar : PubMed/NCBI
15	Harrop JS: Spinal cord injury: Debating the efficacy of methylprednisolone. Neurosurgery. 61:(Suppl 1). S30–S31. 2014. View Article : Google Scholar
16	Walters BC, Hadley MN, Hurlbert RJ, Aarabi B, Dhall SS, Gelb DE, Harrigan MR, Rozelle CJ, Ryken TC, Theodore N, et al: Guidelines for the management of acute cervical spine and spinal cord injuries: 2013 update. Neurosurgery. 60:(Suppl 1). S82–S91. 2013. View Article : Google Scholar
17	Liu T, Jin H, Sun QR, Xu JH and Hu HT: The neuroprotective effects of tanshinone IIA on ß-amyloid-induced toxicity in rat cortical neurons. Neuropharmacology. 59:595–604. 2010. View Article : Google Scholar : PubMed/NCBI
18	Liu Z, Wang J, Huang E, Gao S, Li H, Lu J, Tian K, Little PJ, Shen X, Xu S and Liu P: Tanshinone IIA suppresses cholesterol accumulation in human macrophages: Role of heme oxygenase-1. J Lipid Res. 55:201–213. 2014. View Article : Google Scholar : PubMed/NCBI
19	Yin Y, Sun W, Li Z, Zhang B, Cui H, Deng L, Xie P, Xiang J and Zou J: Effects of combining methylprednisolone with rolipram on functional recovery in adult rats following spinal cord injury. Neurochem Int. 62:903–912. 2013. View Article : Google Scholar : PubMed/NCBI
20	Kaech S and Banker G: Culturing hippocampal neurons. Nat Protoc. 1:2406–2415. 2006. View Article : Google Scholar : PubMed/NCBI
21	Boomkamp SD, McGrath MA, Houslay MD and Barnett SC: Epac and the high affinity rolipram binding conformer of PDE4 modulate neurite outgrowth and myelination using an in vitro spinal cord injury model. Br J Pharmacol. 171:2385–2398. 2014. View Article : Google Scholar : PubMed/NCBI
22	Burnette WN: ‘Western blotting’: Electrophoretic transfer of proteins from sodium dodecyl sulfate-polyacrylamide gels to unmodified nitrocellulose and radiographic detection with antibody and radioiodinated protein A. Anal Biochem. 112:195–203. 1981. View Article : Google Scholar : PubMed/NCBI
23	Basso DM, Beattie MS and Bresnahan JC: A sensitive and reliable locomotor rating scale for open field testing in rats. J Neurotrauma. 12:1–21. 1995. View Article : Google Scholar : PubMed/NCBI
24	Tang Q, Han R, Xiao H, Shen J, Luo Q and Li J: Neuroprotective effects of tanshinone IIA and/or tetramethylpyrazine in cerebral ischemic injury in vivo and in vitro. Brain Res. 1488:81–91. 2012. View Article : Google Scholar : PubMed/NCBI
25	Sun S, Yin Y, Yin X, Cao F, Luo D, Zhang T, Li Y and Ni L: Anti-nociceptive effects of Tanshinone IIA (TIIA) in a rat model of complete Freund's adjuvant (CFA)-induced inflammatory pain. Brain Res Bull. 88:581–588. 2012. View Article : Google Scholar : PubMed/NCBI
26	Xu J, Fan G, Chen S, Wu Y, Xu XM and Hsu CY: Methylprednisolone inhibition of TNF-alpha expression and NF-kB activation after spinal cord injury in rats. Brain Res Mol Brain Res. 59:135–142. 1998. View Article : Google Scholar : PubMed/NCBI
27	A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. N Engl J Med. 323:1207–1209. 1990. View Article : Google Scholar : PubMed/NCBI
28	Ito Y, Sugimoto Y, Tomioka M, Kai N and Tanaka M: Does high dose methylprednisolone sodium succinate really improve neurological status in patient with acute cervical cord injury? A prospective study about neurological recovery and early complications. Spine (Phila Pa 1976). 34:2121–2124. 2009. View Article : Google Scholar : PubMed/NCBI
29	Suberviola B, González-Castro A, Llorca J, Ortiz-Melón F and Miñambres E: Early complications of high-dose methylprednisolone in acute spinal cord injury patients. Injury. 39:748–752. 2008. View Article : Google Scholar : PubMed/NCBI
30	Matsumoto T, Tamaki T, Kawakami M, Yoshida M, Ando M and Yamada H: Early complications of high-dose methylprednisolone sodium succinate treatment in the follow-up of acute cervical spinal cord injury. Spine (Phila Pa 1976). 26:426–430. 2001. View Article : Google Scholar : PubMed/NCBI
31	Chikuda H, Yasunaga H, Takeshita K, Horiguchi H, Kawaguchi H, Ohe K, Fushimi K and Tanaka S: Mortality and morbidity after high-dose methylprednisolone treatment in patients with acute cervical spinal cord injury: A propensity-matched analysis using a nationwide administrative database. Emerg Med J. 31:201–206. 2014. View Article : Google Scholar : PubMed/NCBI
32	Lu J, Ashwell KW and Waite P: Advances in secondary spinal cord injury: Role of apoptosis. Spine (Phila Pa 1976). 25:1859–1866. 2000. View Article : Google Scholar : PubMed/NCBI
33	Mautes AE, Weinzierl MR, Donovan F and Noble LJ: Vascular events after spinal cord injury: Contribution to secondary pathogenesis. Phys Ther. 80:673–687. 2000.PubMed/NCBI
34	Kroemer G, Galluzzi L and Brenner C: Mitochondrial membrane permeabilization in cell death. Physiol Rev. 87:99–163. 2007. View Article : Google Scholar : PubMed/NCBI
35	Korsmeyer SJ, Shutter JR, Veis DJ, Merry DE and Oltvai ZN: Bcl-2/Bax: A rheostat that regulates an anti-oxidant pathway and cell death. Semin Cancer Biol. 4:327–332. 1993.PubMed/NCBI
36	Thornberry NA: The caspase family of cysteine proteases. Br Med Bull. 53:478–490. 1997. View Article : Google Scholar : PubMed/NCBI
37	Miller DK: The role of the Caspase family of cysteine proteases in apoptosis. Semin Immunol. 9:35–49. 1997. View Article : Google Scholar : PubMed/NCBI
38	Xia WJ, Yang M, Fok TF, Li K, Chan WY, Ng PC, Ng HK, Chik KW, Wang CC, Gu GJ, et al: Partial neuroprotective effect of pretreatment with tanshinone IIA on neonatal hypoxia-ischemia brain damage. Pediatr Res. 58:784–790. 2005. View Article : Google Scholar : PubMed/NCBI
39	Meng XF, Zou XJ, Peng B, Shi J, Guan XM and Zhang C: Inhibition of ethanol-induced toxicity by tanshinone IIA in PC12 cells. Acta Pharmacol Sin. 27:659–664. 2006. View Article : Google Scholar : PubMed/NCBI
40	Dong H, Mao S, Wei J, Liu B, Zhang Z, Zhang Q and Yan M: Tanshinone IIA protects PC12 cells from beta-amyloid(25–35)-induced apoptosis via PI3K/Akt signaling pathway. Mol Biol Rep. 39:6495–6503. 2012. View Article : Google Scholar : PubMed/NCBI
41	Lee JM, Yan P, Xiao Q, Chen S, Lee KY, Hsu CY and Xu J: Methylprednisolone protects oligodendrocytes but not neurons after spinal cord injury. J Neurosci. 28:3141–3149. 2008. View Article : Google Scholar : PubMed/NCBI
42	Ege E, Ilhan A, Gurel A, Akyol O and Ozen S: Erdosteine ameliorates neurological outcome and oxidative stress due to ischemia/reperfusion injury in rabbit spinal cord. Eur J Vasc Endovasc Surg. 28:379–386. 2004. View Article : Google Scholar : PubMed/NCBI
43	Topsakal C, Erol FS, Ozveren MF, Yilmaz N and Ilhan N: Effects of methylprednisolone and dextromethorphan on lipid peroxidation in an experimental model of spinal cord injury. Neurosurg Rev. 25:258–266. 2002. View Article : Google Scholar : PubMed/NCBI
44	Fu J, Huang H, Liu J, Pi R, Chen J and Liu P: Tanshinone IIA protects cardiac myocytes against oxidative stress-triggered damage and apoptosis. Eur J Pharmacol. 568:213–221. 2007. View Article : Google Scholar : PubMed/NCBI
45	Sadeghi A, Ebrahimi Seyyed SS, Golestani A and Meshkani R: Resveratrol Ameliorates Palmitate-Induced inflammation in skeletal muscle cells by attenuating oxidative stress and JNK/NF-KB pathway in a SIRT1-independent mechanism. J Cell Biochem. Jan 6–2017.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
46	Chen Y, Wu X, Yu S, Lin X, Wu J, Li L, Zhao J and Zhao Y: Neuroprotection of tanshinone IIA against cerebral ischemia/reperfusion injury through inhibition of macrophage migration inhibitory factor in rats. PLoS One. 7:e401652012. View Article : Google Scholar : PubMed/NCBI
47	Chengke L, Weiwei L, Xiyang W, Ping W, Xiaoyang P, Zhengquan X, Hao Z, Penghui Z and Wei P: Effect of infliximab combined with methylprednisolone on expressions of NF-κB, TRADD, and FADD in rat acute spinal cord injury. Spine (Phila Pa 1976). 38:E861–E869. 2013. View Article : Google Scholar : PubMed/NCBI